Vitrolife Group Annual and Sustainability Report 2024
GOTHENBURG, Sweden, March 27, 2025 /PRNewswire/ -- Vitrolife Group has today published its Annual and Sustainability Report for 2024.
The Annual and Sustainability Report is now available digitally in English and Swedish at www.vitrolifegroup.com. The Annual Report in accordance with European Single Electronic Format (ESEF) is available in Swedish.
Vitrolife Group has chosen not to print or distribute a hard copy of the Annual Report. Those who are unable to access the Annual Report digitally can request a print-out of the Annual Report by contacting Vitrolife Group at [email protected] or call +46 (0) 31 721 80 00.
Gothenburg, Sweden March 27, 2025 VITROLIFE AB (publ)
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 27-03-202509:00 CET.
Sensydia, a clinical-stage non-invasive cardiac assessment company, announced today that University of Minnesota investigators presented positive clinical findings from a recent study evaluating the company's AI-powered, non-invasive Cardiac...
Millions of children are at risk following a devastating 7.7 magnitude earthquake that struck Myanmar on 28 March, compounding an already dire humanitarian situation....
Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.
In 2024, Akeso achieved key success in antibody therapy research...
Eli Lilly and Company today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart...
Medtronic plc , a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evoluttm transcatheter aortic valve replacement (TAVR) system delivers...
Today, Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established...
